دورية أكاديمية
Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study.
| العنوان: | Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study. |
|---|---|
| المؤلفون: | Stanoyevitch A; Department of Mathematics, California State University-Dominguez Hills, Carson, California, USA., Zhang L; Pathology Associates of Anaheim, Anaheim Regional Medical Center, Anaheim, California, USA., Sanz J; University of California at Los Angeles, Clinical and Translational Science Institute, Los Angeles, California, USA., Follett RW; University of California at Los Angeles, Clinical and Translational Science Institute, Los Angeles, California, USA., Bell DS; University of California at Los Angeles, Clinical and Translational Science Institute, Los Angeles, California, USA. |
| المصدر: | Women's health reports (New Rochelle, N.Y.) [Womens Health Rep (New Rochelle)] 2021 Aug 16; Vol. 2 (1), pp. 316-324. Date of Electronic Publication: 2021 Aug 16 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101768931 Publication Model: eCollection Cited Medium: Internet ISSN: 2688-4844 (Electronic) Linking ISSN: 26884844 NLM ISO Abbreviation: Womens Health Rep (New Rochelle) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: New Rochelle, NY : Mary Ann Liebert, Inc., [2020]- |
| مستخلص: | Background: The risks of osteoporosis and breast cancer are increasing in elderly women. Bisphosphonates and denosumab are recommended for treatment of osteoporosis. They have different and overlapping pharmacodynamics and previous studies have shown conflicting results regarding their risk association with breast cancer. We intend to further look into this issue through a comparative study. Methods: Electronic health records of 91,626 women older than 50 years with no previous history of malignancy and no nonbreast cancer during follow-up were retrieved from southern California and retrospectively analyzed using univariate, bivariate, and log-rank tests. Medication use, breast cancer risk, and associated demographic and clinical history were assessed. Results: Over an average of 3.6 years follow-up, the breast cancer relative risks (RRs) counted after 365 days of latency are 1.12 (95% confidence interval [CI]: 0.64-1.97) for denosumab ever users and 0.37 (95% CI: 0.21-0.66) for bisphosphonates ever users, when covariates are comparable. The significant difference is supported by the Log-rank test ( p = 0.0004). Excluding statins coprescribers, the breast cancer RR is 1.31 (0.71, 2.43) in denosumab group and 0.26 (0.11, 0.62) in bisphosphonates group. There is a reduced RR in statins ever users (0.47, 95% CI: 0.38-0.58), and the breast cancer risk difference is not significant between concomitant denosumab/statins and bisphosphonates/statins ever users with RR 0.65 (0.16, 2.58) versus 0.55 (0.26, 1.16), p = 0.692. Conclusions: Our data support an association of lower breast cancer risk with bisphosphonates use in elderly women. We did not observe a lower breast cancer risk in denosumab group; however, our data revealed a potential lower breast cancer risk in denosumab users with concurrent statins use and this requires further study. Competing Interests: No competing financial interests exist. (© Alexander Stanoyevitch et al., 2021; Published by Mary Ann Liebert, Inc.) |
| References: | Int J Cancer. 2012 Sep 1;131(5):E717-25. (PMID: 22161552) Int J Cancer. 2007 Aug 15;121(4):856-62. (PMID: 17397032) JAMA. 2018 Jun 26;319(24):2521-2531. (PMID: 29946735) Calcif Tissue Int. 2011 Apr;88(4):255-62. (PMID: 21253712) Cancer Genet. 2015 May;208(5):241-52. (PMID: 25978957) Postgrad Med. 2010 Nov;122(6):176-87. (PMID: 21084794) JAMA Oncol. 2018 Apr 1;4(4):516-521. (PMID: 29346467) J Clin Oncol. 2010 Aug 1;28(22):3577-81. (PMID: 20567021) Korean J Pain. 2017 Apr;30(2):86-92. (PMID: 28416991) Clin Epidemiol. 2019 Jul 18;11:593-603. (PMID: 31410067) Front Endocrinol (Lausanne). 2018 Sep 11;9:525. (PMID: 30254608) Br J Cancer. 2010 Mar 2;102(5):799-802. (PMID: 20160722) Diabetes Care. 2009 Nov;32 Suppl 2:S384-91. (PMID: 19875586) Br J Cancer. 2018 Nov;119(11):1421-1427. (PMID: 30420611) Eur J Endocrinol. 2018 Jul;179(1):R31-R45. (PMID: 29691303) J Exp Clin Cancer Res. 2019 Jan 8;38(1):12. (PMID: 30621730) Cell Metab. 2016 Mar 8;23(3):479-91. (PMID: 26777690) J Clin Oncol. 2017 Oct 1;35(28):3230-3239. (PMID: 28708471) Endocr Relat Cancer. 2012 Nov 19;19(6):793-803. (PMID: 23035011) Br J Cancer. 2013 Aug 6;109(3):795-806. (PMID: 23868009) J Clin Oncol. 2010 Aug 1;28(22):3582-90. (PMID: 20567009) J Bone Miner Res. 2012 Sep;27(9):1951-8. (PMID: 22532232) JAMA Intern Med. 2014 Oct;174(10):1550-7. (PMID: 25111880) Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):201-6. (PMID: 26762806) |
| فهرسة مساهمة: | Keywords: bisphosphonates; breast cancer; denosumab; osteoporosis; statins |
| تواريخ الأحداث: | Date Created: 20210903 Latest Revision: 20221017 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8409235 |
| DOI: | 10.1089/whr.2020.0120 |
| PMID: | 34476414 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2688-4844 |
|---|---|
| DOI: | 10.1089/whr.2020.0120 |